Terms of
Clearance: This collection is approved under the following terms of
clearance: Upon publishing a new 60-day and 30-day Federal Register
Notice, CMS will provide the public and OMB with a supplemental
document that crosswalks all changes (technical and substantive)
made to the revised ICR. The document should include an explanation
of each change from the previous approval, the reason why the
change is necessary and the citation or reference to the statute,
regulation or guidance document that support the need for the
change. The crosswalk should also address an increase or decrease
in burden for each change.
Inventory as of this Action
Requested
Previously Approved
03/31/2011
36 Months From Approved
12/31/2010
4,988
0
4,725
11,400
0
10,800
0
0
0
CMS requires that MA and PDP
organizations submit a completed formulary and PBP as part of the
annual bidding process. During this process, organizations prepare
their proposed plan benefit packages for the upcoming contract year
and submit them to CMS for review and approval.
PL:
Pub.L. 108 - 173 101 Name of Law: Prescription Drug,
Improvement, and Modernization Act of2003 (MMA)
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.